stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) Net income
PTC Therapeutics, Inc.'s net income for fiscal 2025 was $682.6M, compared with −$363.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$106.0M. Over the past ten years it has ranged from −$626.6M (fiscal 2023) to $682.6M (fiscal 2025) — the current reading is the highest in ten years. PTC Therapeutics, Inc. ranks 434th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $682.6M | — |
| FY2024 | −$363.3M | — |
| FY2023 | −$626.6M | — |
| FY2022 | −$559.0M | — |
| FY2021 | −$523.9M | — |
| FY2020 | −$438.2M | — |
| FY2019 | −$251.6M | — |
| FY2018 | −$128.1M | — |
| FY2017 | −$79.0M | — |
| FY2016 | −$142.1M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$51.7M | — |
| Jun 2026 | $83.5M | — |
| Mar 2026 | −$2.8M | — |
| Dec 2025 | −$135.0M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$77.6M |
| PTCT PTC Therapeutics, Inc. | −$106.0M |
| MANE Veradermics Incorporated compare | −$136.4M |
| CGON CG Oncology, Inc. compare | −$224.4M |
| KOD Kodiak Sciences Inc. compare | −$242.0M |
| COGT Cogent Biosciences, Inc. compare | −$377.2M |
| SRRK Scholar Rock Holding Corporation compare | −$408.6M |
| IMVT Immunovant, Inc. compare | −$538.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$903.9M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on PTCT
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement